Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging.
Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging.
复制标题
DOI：
10.1245/s10434-018-6453-2
复制
发表时间：
2018-07
影响因子：
3.7
通讯作者：
Rosenthal EL
中科院分区：
文献类型：
--
作者：
Tummers WS;Miller SE;Teraphongphom NT;Gomez A;Steinberg I;Huland DM;Hong S;Kothapalli SR;Hasan A;Ertsey R;Bonsing BA;Vahrmeijer AL;Swijnenburg RJ;Longacre TA;Fisher GA;Gambhir SS;Poultsides GA;Rosenthal EL
Operative management of pancreatic ductal adenocarcinoma (PDAC) is complicated by several key decisions during the procedure. Identification of metastatic disease at the outset and, when none is found, complete (R0) resection of primary tumor are key to optimizing clinical outcomes. The use of tumor-targeted molecular imaging, based on photoacoustic and fluorescence optical imaging, can provide crucial information to the surgeon. The first-in-human use of multimodality molecular imaging for intraoperative detection of pancreatic cancer is reported using cetuximab-IRDye800, a near-infrared fluorescent agent that binds to epidermal growth factor receptor. A dose-escalation study was performed to assess safety and feasibility of targeting and identifying PDAC in a tumor-specific manner using cetuximab-IRDye800 in patients undergoing surgical resection for pancreatic cancer. Patients received a loading dose of 100 mg of unlabeled cetuximab before infusion of cetuximab-IRDye800 (50 mg or 100 mg). Multi-instrument fluorescence imaging was performed throughout the surgery in addition to fluorescence and photoacoustic imaging ex vivo. Seven patients with resectable pancreatic masses suspected to be PDAC were enrolled in this study. Fluorescence imaging successfully identified tumor with a significantly higher mean fluorescence intensity in the tumor (0.09 ± 0.06) versus surrounding normal pancreatic tissue (0.02 ± 0.01), and pancreatitis (0.04 ± 0.01; p < 0.001), with a sensitivity of 96.1% and specificity of 67.0%. The mean photoacoustic signal in the tumor site was 3.7-fold higher than surrounding tissue. The safety and feasibilty of intraoperative, tumor-specific detection of PDAC using cetuximab-IRDye800 with multimodal molecular imaging of the primary tumor and metastases was demonstrated.
登录
查看更多内容
DOI：
10.1109/tbme.2012.2183593
发表时间：
2012-05
期刊：
IEEE transactions on bio-medical engineering
影响因子：
--
作者：
Kothapalli SR;Ma TJ;Vaithilingam S;Oralkan O;Khuri-Yakub BT;Gambhir SS
通讯作者：
Gambhir SS
影响因子：
3.7
作者：
Hutteman M;Choi HS;Mieog JS;van der Vorst JR;Ashitate Y;Kuppen PJ;van Groningen MC;Löwik CW;Smit VT;van de Velde CJ;Frangioni JV;Vahrmeijer AL
通讯作者：
Vahrmeijer AL
影响因子：
45.3
作者：
Moore, Malcolm J.;Goldstein, David;Parulekar, Wendy
通讯作者：
Parulekar, Wendy
影响因子：
--
作者：
Tummers, Willemieke S.;Farina-Sarasqueta, Arantza;Swijnenburg, Rutger-Jan
通讯作者：
Swijnenburg, Rutger-Jan
影响因子：
3
作者：
Deeken, J. F.;Shimkus, B.;Zhang, S.
通讯作者：
Zhang, S.